Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

"Although it is hard to look beyond the pandemic right now," says President of the Academy of Medical Sciences Professor Dame Anne Johnson, "I want to stress how important it is that the Academy Fellowship represents the widest diversity of biomedical and health sciences. The greatest health advances rely on the findings of many types of research, and on multidisciplinary teams and cross-sector and global collaboration."

Arjen Dondorp, Rose McGready and Peter Horby

All new Fellows were selected for their exceptional contributions to the advancement of medical science through innovative research discoveries and translating scientific developments into benefits for patients and the wider society.

  • For his pioneering work in the pathophysiology and treatment of severe malaria, antimalarial drug resistance and improvement of intensive care practice in resource-limited settings, Professor Arjen Dondorp of the Centre for Tropical Medicine and Global Health (Nuffield Department of Medicine) becomes a Fellow. He led large multinational trials in Asia and Africa that demonstrated parenteral artesunate is superior to quinine in preventing death from severe malaria in both adults and children. He also organised the pivotal trials showing that artemisinin resistance in falciparum malaria had emerged on the Cambodian-Thai border, starting an extensive research programme on multidrug resistant malaria, an important threat to malaria control.
  • For his tireless clinical and epidemiological research on a wide range of emerging and epidemic infections spanning over 15 years, Professor Peter Horby of the Centre for Tropical Medicine and Global Health (Nuffield Department of Medicine) is named a Fellow at the Academy. He is co-lead of the RECOVERY trial – the world's largest trial of COVID-19 treatments – as well as director of Epidemic Diseases Research Group Oxford (ERGO) and International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC), which are both engaged in several international programmes of clinical and epidemiological research to prepare for and respond to emerging infections that may develop into epidemics or pandemics.
  • Professor Rose McGready of the Centre for Tropical Medicine and Global Health (Nuffield Department of Medicine) is named a Fellow for her leadership of the maternal malaria research sphere. During her tenure at the Shoklo Malaria Research Unit on the Thailand-Myanmar border, she has provided detailed knowledge of the burden and effects of malaria infections on pregnant women and new-borns, leading the world in the safe use of artemisinin derivatives in pregnancy. Focussing on maternal and child health, her research work has been translated into clinical practice and resulted in dramatic improvements in the health of marginalized women in South East Asia and beyond.

The full story is available on the University of Oxford website

Similar stories

RECOVERY trial finds Regeneron’s monoclonal antibody combination reduces deaths for hospitalised COVID-19 patients who have not mounted their own immune response

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial has demonstrated that the investigational antibody combination developed by Regeneron reduces the risk of death when given to patients hospitalised with severe COVID-19 who have not mounted a natural antibody response of their own.

Professors Peter Horby and Guy Thwaites recognised in Queen’s Birthday Honours

The pioneering work of members of the University of Oxford has been recognised in The Queen's Birthday Honours List. The honorands include Professor Peter Horby and six researchers that have played key roles in leading the University’s response to the Coronavirus pandemic, from the development of new vaccines to the discovery of new drug treatments. Professor Guy Thwaites is appointed a Member of the Order of the British Empire.

RECOVERY trial finds aspirin does not improve survival for patients hospitalised with COVID-19

The RECOVERY trial was established as a randomised clinical trial to test a range of potential treatments for patients hospitalised with COVID-19. Patients with COVID-19 are at increased risk of blood clots forming in their blood vessels, particularly in the lungs. Between November 2020 and March 2021, the RECOVERY trial included nearly 15,000 patients hospitalised with COVID-19 in an assessment of the effects of aspirin, which is widely used to reduce blood clotting in other diseases. There was no significant difference in the primary endpoint of 28-day mortality

The COVID-19 International Modelling Consortium (CoMo Consortium) enters a new phase

Created in March 2020 to assist policymakers to make use of existing evidence in mathematical and epidemiological models to inform strategies for minimising the impact of COVID-19, the CoMo Consortium brings together mathematical modellers, epidemiologists, health economists and public health experts from more than 40 countries across Africa, Asia and South and North America.

ASM Editor in conversation with Nick White

Malaria continues to be a major killer, particularly in sub-Saharan Africa, affecting the world’s most vulnerable populations with more than 500,000 deaths per year, most of them African children. Emergence of resistance to antimalarial drugs is major public health issue. American Society for Microbiology Editor Dr Cesar Arias discusses with Professor Sir Nick White the latest information on this rapidly evolving field.

New Pandemic Sciences Centre at the University of Oxford

The University of Oxford announces the launch of a centre of global research collaboration and excellence, the Pandemic Sciences Centre. The need for partnership between academic excellence, industry and public health organisations is one of the key lessons learned from the coronavirus pandemic. This centre will unite disciplines, and sectors, to build agile, equitable partnerships that can tackle complex problems and respond to pandemic threats at any time.